Back

Antigen presentation requirements for effective cDC1-based cancer immunotherapy

Pineda, J. E.; Minowa, T.; Shen, L.; Zhou, Y.; Dyevoich, A. M.; Patel, B.; Schneider, S. M.; Keshari, S.; Saha, A.; Riba, M. N.; Wang, J.; Watowich, S. S.; Gubin, M. M.

2026-01-26 immunology
10.64898/2026.01.24.701412 bioRxiv
Show abstract

Type 1 conventional dendritic cells (cDC1s) are important for generating and sustaining antitumor immunity. Accordingly, the abundance of cDC1s in human tumors correlates with improved outcomes in cancer. Capitalizing on this role, we previously demonstrated that vaccination with in vitro-derived murine cDC1s elicits durable tumor control in multiple preclinical models; however, the immunological mechanisms underlying the efficacy of cDC1 vaccination remain unclear. Here, we examined whether in vitro-derived cDC1s resemble tumor-infiltrating DC populations and whether MHC-I and MHC-II antigen presentation contribute to cDC1-mediated tumor control following vaccination in melanoma. As expected, MHC-I- or MHC-II-deficiency had minimal impact on the transcriptional state of cDC1s in homeostasis or following stimulation with the adjuvant poly dI:dC. Moreover, in vitro-derived cDC1s cultured under steady-state conditions closely resembled tumor-infiltrating cDC1s, whereas their poly dI:dC-stimulated counterparts resembled CCR7+ tumor-infiltrating DC populations, also referred to as mregDCs or LAMP3+ DCs. Our data further show that both MHC-I and MHC-II contribute to tumor control upon cDC1 vaccination, and coexpression of MHC-I and MHC-II on the same cDC1 is necessary for a robust vaccine response. We also identified an important function for host cDC1s in supporting the efficacy of vaccination with in vitro-derived cDC1s, as judged by impaired tumor control in Irf8+32-/- mice, which lack endogenous cDC1s. Overall, these results indicate that effective antitumor responses depend on MHC-I and MHC-II antigen presentation by vaccine-delivered cDC1s, with additional contributions from host cDC1s. Key pointsO_LIIn vitro-generated cDC1s resemble intratumoral DC populations found in mice and humans. C_LIO_LIMHC-I and MHC-II antigen presentation by vaccine-delivered cDC1s contribute to antitumor efficacy. C_LIO_LICoexpression of MHC-I and MHC-II on the same cDC1 enhances vaccine responses. C_LIO_LIAntitumor responses reflect the activity of vaccine and endogenous cDC1s. C_LI

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cancer Immunology Research
34 papers in training set
Top 0.1%
17.1%
2
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.1%
12.0%
3
Cell Reports
1338 papers in training set
Top 2%
12.0%
4
The Journal of Immunology
146 papers in training set
Top 0.3%
4.7%
5
Frontiers in Immunology
586 papers in training set
Top 2%
4.2%
50% of probability mass above
6
iScience
1063 papers in training set
Top 4%
3.9%
7
Cell Systems
167 papers in training set
Top 3%
3.9%
8
eLife
5422 papers in training set
Top 29%
3.2%
9
Science Immunology
81 papers in training set
Top 0.8%
2.3%
10
Immunity
58 papers in training set
Top 2%
2.0%
11
mBio
750 papers in training set
Top 7%
1.8%
12
Nature Communications
4913 papers in training set
Top 49%
1.8%
13
OncoImmunology
22 papers in training set
Top 0.1%
1.8%
14
PLOS Pathogens
721 papers in training set
Top 6%
1.7%
15
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.1%
1.7%
16
JCI Insight
241 papers in training set
Top 4%
1.6%
17
Clinical & Translational Immunology
22 papers in training set
Top 0.1%
1.4%
18
EMBO reports
136 papers in training set
Top 4%
1.3%
19
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 38%
1.2%
20
Cell Reports Medicine
140 papers in training set
Top 6%
0.9%
21
Vaccines
196 papers in training set
Top 3%
0.7%
22
European Journal of Immunology
57 papers in training set
Top 0.6%
0.7%
23
Journal of Experimental Medicine
106 papers in training set
Top 4%
0.7%
24
Journal of Clinical Investigation
164 papers in training set
Top 7%
0.7%
25
Journal of Virology
456 papers in training set
Top 4%
0.7%
26
Cell
370 papers in training set
Top 18%
0.7%
27
Mucosal Immunology
42 papers in training set
Top 0.4%
0.7%
28
Scientific Reports
3102 papers in training set
Top 79%
0.6%
29
Cellular & Molecular Immunology
14 papers in training set
Top 2%
0.6%
30
Theranostics
33 papers in training set
Top 2%
0.6%